Movement Disorder Virtual University WE MOVE
Research News
E-MOVE - Research News Service Subscribe to E-MOVE

Search Research News
Any Words All Words Exact Phrase

E-MOVE Archives 2004

ID date title
627 1/8/2004 Neuroscience 2003 Reports Available at MDVU
628 1/12/2004 Dyskinesia Benefit of Amantadine is Short-Lived
629 1/23/2004 Pramipexole for REM Sleep Behavior Disorder
630 1/23/2004 Comorbidities in Parkinsonism
631 1/26/2004 Announcement: Innovative Educational Opportunity from WE MOVE
632 2/4/2004 Trehalose Sugar Reduces Aggregation in HD Mice
633 2/20/2004 Incidence and Consequences of Spasticity After Stroke
634 2/27/2004 Pathogenic Role of Excess Normal Alpha-Synuclein Confirmed in Second Family
635 3/15/2004 STN DBS Improves Sleep
636 3/23/2004 Announcement: WE MOVE Launches Online Educational Course on Pediatric Movement Disorders
637 3/26/2004 Long-term Follow-up of BTX-A for Cervical Dystonia
638 3/26/2004 Apomorphine Journal Supplement (Contents)
639 4/2/2004 Essential Tremor: Experimental Therapies
645 4/9/2004 Dystonia Cellular Pathophysiology, Alternative Medicine Use
647 4/12/2004 RLS Prevalence, Co-Morbidities
648 4/13/2004 No Loss of Olfaction in Parkin PD
650 4/20/2004 Rasagiline May Slow PD Decline; Pergolide and Valvular Disease
652 4/21/2004 PARK6 Protein Identified; Case-Based Learning Modules Available
654 4/22/2004 FDA Approves Apomorphine Injectable; Trial of Fast-Dissolving Selegiline in PD
664 5/7/2004 Parkin Interacts with Ataxin2 and Synaptic Vesicle Proteins (AAN 2004)
666 5/11/2004 Long-term Results of GDNF Pilot Trial; Gene Therapy in Animal Model (AAN 2004)
668 5/12/2004 Dystonia: Altered Biochemistry of TorsinA, Genetics
670 5/13/2004 Essential Tremor Update (AAN 2004)
672 5/15/2004 Genetic Risk Factors in PD, part 1 (AAN 2004)
674 5/17/2004 RLS Prevalence, Diagnosis, and Severity (AAN 2004)
676 5/17/2004 Genetic Risk Factors for PD, part 2 (AAN 2004)
678 5/18/2004 Hallucinations in Advanced PD (AAN 2004)
680 5/18/2004 Announcement: New Educational Efforts from WE MOVE
682 5/19/2004 Dopamine Agonists for RLS (AAN 2004)
684 5/20/2004 Acetylcholinesterase Inhibitors for PD Dementia (AAN 2004)
686 5/24/2004 PD: Medication Errors, Most Troubling Symptoms (AAN 2004)
688 5/24/2004 RLS: Pilot Trials of New Therapies (AAN 2004)
690 5/25/2004 PD Dopamine Agonist Treatment (AAN 2004)
692 5/26/2004 PD: New Treatment Strategies in Animal Models (AAN 2004)
694 5/26/2004 Pediatric Movement Disorders (AAN 2004)
696 5/27/2004 BTX for Dystonias (AAN 2004)
698 5/28/2004 Psychogenic Movement Disorders (AAN 2004)
700 5/28/2004 Rasagiline Versus Entacapone in PD (AAN 2004)
702 5/31/2004 Tardive Dyskinesia Treatment and Risk Factors (AAN 2004)
704 6/28/2004 Environmental Risk Factors in PD
706 6/28/2004 ET Gene, FXTAS Prevalence
716 6/30/2004 Six-Month Double-blind GDNF Results Show No Benefit
718 7/5/2004 Botulinum Toxin News (MovDis 2004)
720 7/9/2004 Dystonia Research from Movement Disorders Congress 2004
722 7/19/2004 PD Treatment Update from Movement Disorders Congress 2004
728 7/22/2004 Miscellaneous Issues in Parkinson’s Disease from Movement Disorders Congress 2004
730 8/5/2004 Neuropsychiatric Aspects and Suicide Risk of DBS (MovDis Congress 2004)
732 8/21/2004 Apathy and Testosterone; Sexuality After DBS in PD
734 8/21/2004 Systemic Proteasome Inhibitors Replicate Key Features of PD
736 8/21/2004 More Valvular Heart Disease from Ergot-Derived Dopamine Agonists
756 9/21/2004 New Case Study Added to Online Course: The Diagnosis and Management of Pediatric Movement Disorders
749 9/21/2004 TorsinA Functional Studies; Gene for Rapid-Onset Dystonia Parkinsonism
748 9/21/2004 BDNF, Mitochondrial Pore, RNAi in Polyglutamine diseases
755 9/21/2004 DBS for PD and Dystonia: Long-Term Results
760 9/29/2004 PD—Pain, Physical Therapy, Safinamide
762 10/8/2004 GDNF Withdrawn by Manufacturer; A vs B in CD (ANA 2004)
764 10/18/2004 Spasticity Treatment, AIMs Following Stroke; DBS Programmers' Forum
769 10/26/2004 PD Genetics Update

 

All contents copyright © WE MOVE 2008. This page last modified 3/5/2008.